

Phenotype and Molecular Detection of Clarithromycin and Levofloxacin Resistance in *Helicobacter pylori* Clinical Isolates in Beijing

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Chong-Hou Lok 

Dong Zhu

Jia Wang

Yu-Tang Ren

Xuan Jiang

Shu-Jun Li

Xiu-Ying Zhao

Beijing Tsinghua Changgung Hospital,
School of Clinical Medicine, Tsinghua
University, Beijing, People's Republic of
China

Introduction: Understanding drug resistance is important in drug selection for *Helicobacter pylori* (*H. pylori*) eradication, and drug resistance data are lacking in Beijing.

Purpose: This cross-sectional study aimed to isolate *H. pylori* from patients with gastro-duodenal diseases and to analyze drug resistance to clarithromycin (CLA) and levofloxacin (LEV), which are used frequently in China.

Patients and Methods: One hundred and seventy-six patients with gastroduodenal diseases undergoing gastroduodenoscopy were selected by convenient sampling. Gastric mucosa samples were cultured and sub-cultured using a new medium broth. Active *H. pylori* strains were confirmed by microscopy observation as Gram-negative curved bacilli with positive test results for urease, oxidase, and catalase, and *H. pylori* 16S rRNA amplification by polymerase chain reaction (PCR). CLA and LEV resistance was identified by minimum inhibitory concentration (MIC) tests and sequencing of 23S rRNA, *gyrA*, and *gyrB* genes.

Results: From the 176 clinical samples, 112 (112/176, 63.6%) were confirmed with *H. pylori* infection and 65 (65/176, 36.9%) active *H. pylori* strains were obtained and further confirmed by MIC assay. Overall, the rates of CLA-resistant and LEV-resistant mutations in the 112 samples were 50.9% and 33.0%, respectively. Mutation related to CLA resistance was A2143G in the 23S rRNA gene and mutations associated with LEV resistance were N87K, D91G, and D91Y in the *gyrA* gene. Of 112 samples, 22 (19.6%) presented dual resistance to CLA and LEV. Resistance of the *H. pylori* strains to CLA ($r=0.846$, $P<0.001$) and LEV ($r=0.936$, $P<0.001$) had a strong correlation in phenotypic and genotypic level.

Conclusion: The results indicated that resistance of CLA and LEV is severe among patients with gastroduodenitis. A good consistency could be found as to drug resistance between genotypic or phenotypic assay, suggested extending the detection of *H. pylori* drug resistance from the MIC method to a genotypic assay.

Keywords: *Helicobacter pylori*, clarithromycin, levofloxacin, antibiotic resistance

Introduction

Helicobacter pylori (*H. pylori*) is one of the most prevalent pathogens in the world, affecting 50% of the world's population.^{1,2} It was first identified in samples of gastric biopsies by Warren and Marshall in Australia in 1983.³ *H. pylori* is a spiral-shaped Gram-negative facultative anaerobic bacterium, which is difficult to culture, and is reported to have huge genetic variation.^{4,5} Strains of *H. pylori* can be divided into two major subpopulations, based on their ability to produce a 120–145 kDa

Correspondence : Xiu-Ying Zhao
Beijing Tsinghua Changgung Hospital,
School of Clinical Medicine, Tsinghua
University, Beijing 10220, People's
Republic of China
Email zxya00340@btch.edu.cn

immunodominant protein called cytotoxin-associated gene A antigen (CagA), which is closely associated with severe atrophic gastritis and adenocarcinoma.^{6,7} This heterogeneity of *H. pylori* strains is thought to be associated with a strain's ability to cause upper gastrointestinal diseases such as chronic gastritis, peptic ulcer, mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric cancer.^{8,11} Recently, it has been suggested that *H. pylori* may be associated with extraintestinal diseases, including immune thrombocytopenic purpura, refractory iron deficiency anemia, and vitamin B12 deficiency.^{1,12}

In China, the infection rate of *H. pylori* has reached to 50–60%¹³ Common antibiotics for the eradication of *H. pylori* include amoxicillin (AMX), clarithromycin (CLA), levofloxacin (LEV), metronidazole (MTZ), and tetracycline (TET).^{14,15} According to the Maastricht IV/Florence consensus report, it is recommended to use a proton-pump-inhibitor (PPI) in combination with CLA and AMX or MTZ for triple therapy and with the addition of bismuth for quadruple therapy as the treatment of choice, due to increasing antimicrobial resistance.^{1,16}

Antibiotic resistance is the main factor accounting for the unsuccessful eradication of *H. pylori*. CLA has been extensively used because it was considered to be an efficient antibiotic during the past 10 years.¹⁷ With the increasing resistance of *H. pylori* to CLA, there is growing concern that the eradication of *H. pylori* infection may decline.¹⁸ Considering that CLA should be used with caution in countries with CLA resistance rates higher than 15–20%, regional data about *H. pylori* resistance to CLA is critical to clinical practice.¹⁹ Other treatment options including quinolones, such as LEV, have been evaluated as alternatives to standard antibiotics against *H. pylori*.²⁰ Cross-resistance to LEV and other quinolones, which have been widely used clinically,¹⁵ has been reported. Although the LEV-containing regimen is not recommended for primary treatment,²¹ the prevalence of LEV usage and the high resistance rates to other quinolones will inevitably decrease the *H. pylori* eradication rate.

Previous studies have found that CLA resistance is caused by point mutations (adenine–guanine transition) at positions 2142 (11.7%) and 2143 (69.8%) of the 23S *rRNA* gene, preventing macrolides from binding to the 50S nucleosomes.²² The mechanism of LEV resistance is related to mutations in the quinolone resistance-determining regions (QRDRs) of the *gyrA* gene.²³ Although mutations in the *gyrB* gene have been reported in LEV-resistant strains in Japan, these mutations usually occur in conjunction with *gyrA* mutation.²⁴

Despite the growing drug resistance in *H. pylori*, it is not a priority in clinical practice to perform *H. pylori* culture and drug susceptibility tests, given that the culture of *H. pylori* as a microaerobic bacteria is a tedious job with prolonged turn-around-time and low isolation rate. Most physicians choose the eradication program based on clinical practice, which makes the situation even worse by producing new drug-resistant strains. Periodical and regional data on *H. pylori* antibiotic resistance would facilitate the rational use of antibiotics; however, such data are seldom reported in Beijing.

In this study, *H. pylori* was isolated from the biopsy gastric mucosa of patients with chronic gastroduodenitis by an improved and rapid *H. pylori* culture method, with the purpose to find the situation of *H. pylori* drug resistance to CLA and LEV, at phenotypic and genotypic levels, and to evaluate the correlation between the two methods.

Patients and Methods

Patient Recruitment and Ethics Statement

One hundred and seventy-six patients were selected for *H. pylori* culture from 6779 cases by convenient sampling. All the patients came to pursue medical consultation at the Gastroenterology Department of Beijing Tsinghua Changgung Hospital during April 2018 to April 2019. Only those patients who accepted a gastroscopy check on Tuesday and Wednesday mornings, who presented positive results of 13C-Urea Breath Test (13C-UBT) within one month, and who had never been treated with antibiotics or PPI or had discontinued previous treatment for more than a month were selected for *H. pylori* culture. Samples of gastric mucosa in the antrum or fundus were taken when they were undergoing gastroduodenoscopy.

In accordance with the Declaration of Helsinki, this study was approved by the Institutional Review Board of Beijing Tsinghua Changgung Hospital (No. 18023-0-02). All the patients signed informed consent prior to their gastroduodenoscopy, including consent access to pathological tissue samples.

H. pylori Culture and Active Strain Isolation

The gastric mucosa samples were transferred into a one-step commercial isolation broth with rich broth medium and indicator (Yimin Bioengineering, Guangdong, China) and immediately placed in a 37°C incubator. According to the manufacturer's instruction, the sample was considered to be

H. pylori-positive when the culture medium turns red and some floating granules could be seen. The more granules, the larger the bacterial quantity. After 5 days of culture, no visible change indicated *H. pylori*-negative. The growth of active *H. pylori* was accelerated and the culture was purified by transferring 100–200 μ L of the positive culture medium into another tube containing fresh isolation broth. Strains of *H. pylori* were identified by microscopy observation as Gram-negative curved bacilli and positive test results for urease, oxidase, catalase, and polymerase chain reaction (PCR) using a specific primer to amplify *H. pylori* 16S *rRNA*.²⁵ All active strains were stored at -80°C in special frozen broth (Yimin Bioengineering, Guangdong, China) for subculture, and both drug susceptibility test and PCR for sequencing.

MIC Determination

MIC was determined by broth microdilution at the lowest concentration, according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI)²⁶ and the manufacturer's instructions. Based on the recommendations of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), *H. pylori* 26695 was used as the quality control strain. The resistance breakpoints of CLA and LEV were defined as >0.5 $\mu\text{g}/\text{mL}$ and >1 $\mu\text{g}/\text{mL}$, as previously suggested.²⁷

PCR Amplification and Sequencing

The *H. pylori* genome was extracted by TIANamp Bacteria DNA Kit (Tiangen Biotech, Beijing, China) and using the 112 primary culture-positive samples. Briefly, 200 μ L culture broth from each sample was centrifugated to precipitate the bacteria, and the precipitate was used for DNA extraction and PCR. Antibiotic resistance of *H. pylori* to CLA includes A2142C, A2142G, and A2143G in 23S *rRNA*²⁸ and resistance mutations to LEV include *gyrA*, *gyrB*,²⁹ which were amplified using previously reported primers (Table 1). The PCR products were obtained by agarose gel electrophoresis. Positive PCR products were sent to BGI Technology Company (Shengzhen, China) for sequencing using the PCR primers. The sequences were then compared with the published sequence of the *H. pylori* 23S *rRNA*, *gyrA* and *gyrB* genes (GenBank accession number NC_000915.1).

Statistical Analysis

The result of MIC drug sensitivity and the genotype mutations of the *H. pylori* is compared by Spearman correlation

Table 1 Primer Sequences for the Amplification of the Drug Resistance Gene of *H. pylori*

Gene	Sequence (5'→ 3')	Product Length (bp)
16S <i>rRNA</i> ²⁵	CTGGAGAGACTAAGCCCTCC	446
	AGGATCAAGGTTTAAGGATT	
<i>gyrA</i> ²⁸	AGCTTATTCCATGAGCGTGA	582
	TCAGGCCCTTTGACAAATTC	
<i>gyrB</i> ²⁸	CCCTAACGAAGCCAAAATCA	465
	GGGCGCAAATAACGATAGAA	
23S <i>rRNA</i> ²⁷	CCACAGCGATGTGGTCTCAG	425
	CTCCATAAGAGCCAAAGCCC	

analysis, with 0.05 as the statistical significance level. SPSS 22.0 was used for all statistical analyses (SPSS Inc., Chicago, IL, USA).

Results

The Culture and Isolation of Active *H. pylori* Strains

The 176 patients aged from 17 to 82, with a mean age of 48.4. Of the 176 patients, 93 (52.8%) were male, 83 (47.2%) were female, and the ratio of male to female was 1.1.

Of the 176 samples, 112 were confirmed to be *H. pylori*-positive by primary culture and were further confirmed by 16S *rRNA* PCR; the overall detection rate was 112/176 (63.6%). By subculturing the 112 samples, we finally obtained 65 active *H. pylori* strains. No active strain was isolated from the other 47 primary culture-positive samples, which could be a result of either contamination or *H. pylori* dying during the subculture process. The isolation rate of active strains was 36.9% (65/176) and the 65 strains were used for phenotype study by the MIC method. Figure 1 presents the flowchart of this study.

Antibiotic Susceptibility by MIC

The MICs of CLA and LEV were determined in 65 active strains of *H. pylori*. Based on the EUCAST breakpoints, the prevalence of drug resistance to CLA (MIC >0.5 $\mu\text{g}/\text{mL}$) and LEV (MIC >1 $\mu\text{g}/\text{mL}$) was 52.3% (34/65) and 38.5% (25/65), respectively. Of the 65 *H. pylori* strains, 35.4% (23/65) were sensitive to both CLA and LEV, while




Figure 1 Flowchart of this study.

26.2% (17/65) were dual resistant to CLA and LEV (Table 2).

Characteristics of the Drug-Resistant Gene to CLA and LEV

Of the 112 samples with positive results in the primary culture used for molecular tests, the frequency of resistant genes to CLA and LEV was 50.9% (57/112) and 33.0% (37/112), respectively. The CLA-resistant mutation was all mapped to A2143G (Figure 2A). For *gyrA* resistance, 13 of the strains had mutations corresponding to Asp-91 (C271T, A272G) and 24 had mutations corresponding to Asn-87 (C261A, C261G) (Figure 2B). We did not find any mutation in the *gyrB* gene. There were 19.6% (22/112) of

the strains showed dual resistance to both CLA and LEV (Table 3).

Comparison of the Genotype and Phenotype of CLA and LEV Resistance

Genotype and phenotype resistance to the two drugs were compared in the 65 *H. pylori* strains between MIC results and the presenting of drug-resistant mutation. Briefly, no drug-resistant mutation was detected from 27 strains, among which 23 (23/27) strains were sensitive to CLA and LEV by MIC ($r=0.813$, $P<0.001$). As shown in Table 2, the results of the Spearman correlation test indicated that resistance of the *H. pylori* strains to CLA ($r=0.846$, $P<0.001$) and LEV ($r=0.936$, $P<0.001$) had a strong correlation to the presenting

Table 2 Spearman Correlation Between Phenotype and Genotype of 65 *H. pylori* Strains

Susceptibility Test Results	MIC Results	Molecular Results	r	P-value
Total sensitive	23 (35.4%)	27 (41.5%)	0.813	<0.001
Total resistance				
CLA	34 (52.3%)	33 (50.8%)	0.846	<0.001
LEV	25 (38.5%)	23 (35.4%)	0.936	<0.001
Dual resistance	17 (26.2%)	18 (27.7%)	0.962	<0.001

Abbreviations: CLA, clarithromycin; LEV, levofloxacin; MIC, minimum inhibitory concentration.

A
 ATCC 26695 CCGCGCAAGACGGAAGACCCCGTGGACCTTTACTACAA 2167
 Mutant CCGCGCAAGACGGAAGACCCCGTGGACCTTTACTACAA

B
 ATCC 26695 YHPHGDNAVYDALVRMAQDFSMRLELVDGQGNFGSIDGDN 120
 Mutant N87K YHPHGDNAVYDALVRMAQDFSMRLELVDGQGNFGSIDGDN
 Mutant D91G YHPHGDNAVYDALVRMAQDFSMRLELVDGQGNFGSIDGDN
 Mutant D91Y YHPHGDNAVYDALVRMAQDFSMRLELVDGQGNFGSIDGDN

Figure 2 Comparison of 23S rRNA allele and *gyrA* allele sequences of *H. pylori*. **(A)** 23S rRNA allele sequences of *H. pylori*. Sequence alignment showed that 23S rRNA allele was in the V region. Part of the RNA sequence of 23S rRNA V region shows the allele sequence found in different *H. pylori* clinical isolates. Compared with ATCC 26695, the mutant was 2143 adenine-guanine mutation. The point mutation has been marked black. **(B)** *gyrA* allele sequences of *H. pylori*. Sequence alignment showed that the amino acid sequence of *gyrA* was in QRDRs. Compared with ATCC 26695, mutant N87K was 87 asparagine-lysine mutations, mutant D91G was 91 aspartic acid-glycine mutations, and mutant D91Y was 91 aspartic acid-tyrosine mutations. The point mutation has been marked black.

of reported drug-resistant mutations. There were 18 strains of *H. pylori* presenting resistance genes to CLA and LEV in 23S rRNA and *gyrA* gene altogether (Table 4). However, 7 strains showed inconsistencies in the phenotype and genotype resistance to CLA and LEV, with 5 of them exhibiting inconsistencies to CLA, 3 of them indicating drug resistance by MIC but no mutation, 2 of them with mutation but no MIC resistance; the other 2 strains showed inconsistencies in LEV resistance in that drug resistance was detected while no related mutation was found (Table 5).

Discussion

The present study was a cross-sectional study based in a tertiary hospital in Beijing, with the purpose of getting updated regional data about *H. pylori* resistance to two widely used antibiotics (CLA and LEV) in clinical practice

in Beijing, and comparing the phenotype resistance (results of the MIC tests) to the genotype resistance (gene mutations associated with drug resistance). MIC is still the golden standard for antibiotic resistance, providing that live bacteria strains are available. One hundred and seventy-six non-repetitive gastric mucosa samples were accepted for *H. pylori* culture following a convenient rule as described, but the researcher had no bias on the sampling of the culture. From those 176 patients, 112 (63.6%) were confirmed with *H. pylori* infection by *H. pylori* primary culture and 16S rRNA PCR, and 65 (36.9%) active *H. pylori* strains were obtained after subculture. The culture of *H. pylori* has seldom been used for clinical diagnosis due to low efficiency, and some laboratories used it only for research purposes.³⁰ In this study, we used the commercial improved broth of one-step culture as the separation medium, with the gastric mucosa

Table 3 Gene Mutations Related to CLA and LEV Resistance of the 112 *H. pylori* Positive Samples

Antibiotics	Sample Type	n/N (%)	Mutations	Percentage of Mutation
CLA	AS	33/65 (50.8%)	A2143G	33/33 (100%)
	NS	24/47 (51.1%)	A2143G	24/24 (100%)
LEV	AS	23/65 (35.4%)	N87K D91Gly D91Y	15/23 (65.2%) 7/23 (30.5%) 1/23 (4.3%)
	NS	14/47 (29.8%)	N87K D91Gly D91Y	9/14 (64.2%) 4/14 (28.6%) 1/14 (7.0%)
CLA + LEV	AS	18/65 (27.7%)	A2143G + N87K A2143G + D91Gly A2143G + D91Y	11/18 (61.1%) 6/18 (33.3%) 1/18 (5.6%)
	NS	4/47 (8.5%)	A2143G + N87K A2143G + D91Gly	3/4 (75%) 1/4 (25%)

Abbreviations: A, adenine; AS, active strain; CLA, clarithromycin; D, aspartic acid; G, guanine; Gly, glycine; K, lysine; LEV, levofloxacin; N, asparagine; Y, tyrosine; NS, no strain (ie, no active *H. pylori* strain isolated from the sample).

Table 4 18 *H. pylori* Strains with MIC Resistance to Both CLA and LEV and the Corresponding Mutations

Strains Number	MIC ($\mu\text{g/mL}$)		Mutations of 23S rRNA	Mutations of <i>gyrA</i>
	CLA	LEV		
3	8	16	A2143G	N87K
5	32	8	A2143G	D91Gly
7	16	4	A2143G	N87K
10	16	8	A2143G	D91Gly
14	64	8	A2143G	N87K
19	4	4	A2143G	N87K
28	32	16	A2143G	D91Gly
38	≥ 256	4	A2143G	D91Gly
39	64	4	A2143G	N87K
40	64	8	A2143G	N87K
43	64	8	A2143G	D91Gly
44	16	4	A2143G	D91Gly
48	8	8	A2143G	N87K
52	8	4	A2143G	N87K
54	16	4	A2143G	N87K
58	16	4	A2143G	D91Y
65	≥ 256	128	A2143G	N87K
37	< 0.0156	16	A2143G	N87K

Note: CLA > 0.5 $\mu\text{g/mL}$ is sensitive, LEV > 1 $\mu\text{g/mL}$ is sensitive.

Abbreviations: A, adenine; CLA, clarithromycin; D, aspartic acid; G, guanine; Gly, glycine; K, lysine; LEV, levofloxacin; MIC, minimal inhibitory concentration; N, asparagine; Y, tyrosine.

Table 5 Seven Strains with Discordant Phenotype to Genotype Resistance to CLA and LEV

Strain Number	MIC ($\mu\text{g/mL}$)		Mutations of 23S rRNA	Mutations of <i>gyrA</i>
	CLA	LEV		
1	4	0.25	–	–
18	0.03	2	–	–
21	0.06	4	–	–
23	2	0.06	–	–
47	8	0.25	–	–
22	0.06	0.25	A2143G	–
37	< 0.0156	16	A2143G	N87K

Notes: CLA > 0.5 $\mu\text{g/mL}$ is sensitive, LEV > 1 $\mu\text{g/mL}$ is sensitive.

Abbreviations: A, adenine; CLA, clarithromycin; G, guanine; LEV, levofloxacin; MIC, minimal inhibitory concentration; –, no mutation.

samples not needing to be ground and could be directly added to the broth. The one-step medium also includes antibiotics to prevent the growth of other bacteria and growth indicator of 2, 3, 5-triphenyltetrazoliumchloride (TTC) to inhibit some bacteria and make it easier for researchers to judge the positive results of the culture. This method can reduce the experimental steps and increase the chance of obtaining a pure culture. We finally isolated 65 live *H. pylori* strains that could be analyzed by the MIC tests.

The positive rate was 36.9%, which was similar to other studies.³¹ To overcome the lower efficiency in obtaining positive culture, current guidelines recommend culture and antibiotic susceptibility tests after two rounds of failed *H. pylori* eradication attempts.¹ Where testing is unavailable, epidemiological data on *H. pylori* resistance are essential to help the rational use of antibiotics.

It was realized that molecular assay might increase the sensitivity of *H. pylori* identification significantly compared to bacterial culture. Some molecular assays were adapted to use gastric tissues or stool samples to detect *H. pylori* and antibiotic resistance and to identify the recurrence or reinfection after eradication, in addition to providing new means for understanding clinical and epidemiological drug resistance of *H. pylori*.³¹

Base on the Maastricht V/Florence consensus report, if the local CLA resistance rate exceeds 15%, it is recommended to avoid using CLA-based triple therapy.²¹ Among the 112 clinical samples, 57 (50.1%) were detected as resistant to CLA. The rate was much greater than the 15% limitation, suggesting that the CLA-based triple regime was not suitable for the treatment of *H. pylori* infection in this region. Resistance to CLA is usually associated with point mutations in the 23S rRNA gene, especially at loci of 2142 and 2143.²² In our study, all mutations were A2143G, the most predominant mutation reported previously.²²

Of the 112 samples, genotypic assay indicated that 37 (33.0%) were resistant to LEV. Among these LEV-resistance samples, we did not find any mutation in the *gyrB* gene; all mutations were found in the *gyrA* gene. N87K and D91G were more frequent than others. Resistance to LEV was due to substitution at positions 87 (K) and 91 (G, Y) of *gyrA* QRDRs. Our results were consistent with other reports indicating that D91G and N87K appeared to be the major mutations described worldwide.³³

It has been indicated that CLA resistance increased annually in a linear manner and was associated with increasing age.³⁴ In neighboring regions of Japan and South Korea, the CLA resistance rate increased from 1.8% in 1996 to 27.1% in 2008³⁵ and 11% in 2005 to 60% in 2009,³⁶ respectively. In the United States, the CLA resistance rate increased from 9.1% in 2009–2010 to 24.2% in 2011–2013.³⁷ In a US study focused on children, the rate of CLA resistance was as high as 50%.³⁷ Some guidelines suggest that LEV should be part of rescue treatment based on antibiotic susceptibility testing.^{1,38} The resistance rate of LEV in Italy and Portugal is also 22–24%.^{39,40} Other studies indicated that LEV resistance

decreased annually, with resistance for a certain cohort at 3.5%.³⁴ In a multicenter retrospective study of children in China, the rate of LEV resistance was low, accounting for 6.7% of the study population,⁴¹ because quinolones are not indicated in children younger than 18 years old. In a multicenter study among patients who had gastroduodenoscopy in Morocco, the rate of LEV resistance was 11%, and these patients had never received treatment.⁴² In Nepal, the primary LEV resistance rate was as high as 42.9%, which might lead to cross-resistance of other quinolones.⁴³ Our results showed that the rate of CLA resistance was 50.9% and the rate of LEV resistance was 33.0%, which indicated a severe situation of *H. pylori* resistance to both CLA and LEV. In addition, we found that 22 (19.6%) of the 112 samples had dual resistance genes to CLA (*23S rRNA*) and LEV (*gyrA*). This is the first report showing *H. pylori* dual resistance to CLA and LEV in the geographic region of Beijing, suggesting that *H. pylori* eradication rate would be significantly reduced with a CLA plus LEV regimen.

By comparing genotypic and phenotypic characteristics of CLA and LEV resistance of the 65 strains, it is obvious that most of the genotypic results were consistent with the phenotypic results. The findings supported the rationale of using the molecular method to predict antibiotic-resistant of *H. pylori* instead of MIC assay. However, 7 strains had different results between the genotypic and phenotypic tests. Two strains had CLA-resistant A2143G, but it was sensitive to CLA in the MIC test. The other 5 strains showed no mutations in drug resistance genes, but 2 were resistant to CLA, and 3 were resistant to LEV. In this study, we focused on previously reported mutations. However, there could be other mutations that have not yet been identified and the samples should be subjected to follow-up studies (Table 5). The results also suggested that there might be inconsistencies between the results of molecular detection and phenotypic analysis, and this possibility should be taken into consideration in clinical practice.

Conclusion

Our study indicated that the resistance of *H. pylori* to CLA and LEV in Beijing is in a serious situation, with dual resistance to the two drugs reaching 19.6%. It would be necessary to select a therapeutic regime based on information on *H. pylori* resistance. Information on the drug-resistant gene was well correlated to MIC assay and could serve as an alternative to support drug selection in a more convenient way than MIC assay. However, there were some limitations to this study. First, it was a cross-

sectional study and previous treatments were not taken into account; therefore, previous antibiotic treatments might have affected the *H. pylori* isolation and presentation of the resistance. Secondly, the selection of the 176 patients for *H. pylori* isolation followed a convenient sampling manner but not random design, though the researcher had no interference on sampling, but the typical of this study is discounted. Third, the phenotypic results were considered to be the standard method for antibiotic resistance estimation, but the MICs used to define drug resistance were inconsistent in different studies, leading to bias when comparing our drug resistance to others.

Acknowledgment

Many thanks to our colleagues in the microbiology lab for assistance with the experiments. We also appreciate Gaohui Nong at the Zhu Hai Health School for providing technical instructions when we performed the *H. pylori* culture. This study was supported by Beijing Tsinghua Changgung Hospital Fund (Grant No. 12017C1019).

Disclosure

The authors declare no potential conflicts of interest.

References

1. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of helicobacter pylori infection—the maastricht iv/florence consensus report. *GUT*. 2012;61(5):646–664. doi:10.1136/gutjnl-2012-302084
2. Williams MP, Pounder RE. Helicobacter pylori: from the benign to the malignant. *Am J Gastroenterol*. 1999;94(11 Suppl):S11–6. doi:10.1016/S0002-9270(99)00657-7
3. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *LANCET*. 1984;1(8390):1311–1315. doi:10.1016/S0140-6736(84)91816-6
4. Atherton JC, Peek RJ, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in *vacA*, the vacuolating cytotoxin gene of Helicobacter pylori. *GASTROENTEROLOGY*. 1997;112(1):92–99. doi:10.1016/S0016-5085(97)70223-3
5. Logan RP, Berg DE. Genetic diversity of Helicobacter pylori. *LANCET*. 1996;348(9040):1462–1463.
6. Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of helicobacter pylori associated with cytotoxicity and duodenal ulcer. *P NATL ACAD SCI USA*. 1993;90(12):5791–5795. doi:10.1073/pnas.90.12.5791
7. Hatakeyama M. Helicobacter pylori CagA—a bacterial intruder conspiring gastric carcinogenesis. *Int J Cancer*. 2006;119(6):1217–1223. doi:10.1002/ijc.21831
8. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. *J Clin Invest*. 2004;113(3):321–333. doi:10.1172/JCI20925
9. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European society of gastrointestinal endoscopy (ESGE), European helicobacter study group (EHSg), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *ENDOSCOPY*. 2012;44(1):74–94. doi:10.1055/s-0031-1291491

10. Vakil N, Megraud F. Eradication therapy for *Helicobacter pylori*. *GASTROENTEROLOGY*. 2007;133(3):985–1001. doi:10.1053/j.gastro.2007.07.008
11. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. *LANCET*. 2008;372(9636):392–397. doi:10.1016/S0140-6736(08)61159-9
12. Banic M, Franceschi F, Babic Z, Gasbarrini A. Extragastric manifestations of *Helicobacter pylori* infection. *HELICOBACTER*. 2012;17 (Suppl 1):49–55. doi:10.1111/j.1523-5378.2012.00983.x
13. Hooi J, Lai WY, Ng WK, et al. Global prevalence of *Helicobacter pylori* infection: systematic review and meta-analysis. *GASTROENTEROLOGY*. 2017;153(2):420–429. doi:10.1053/j.gastro.2017.04.022
14. Li M, Gao F. Progress in research on therapeutic regimen for *Helicobacter pylori* eradication. *Chin J Gastroenter*. 2016;10:623–625.
15. Fifth Chinese LW. National consensus report on the management of *Helicobacter pylori* infection. *Chin J Gastroenter*. 2017;6:321–324.
16. Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. *GASTROENTEROL CLIN N*. 2015;44(3):537–563. doi:10.1016/j.gtc.2015.05.003
17. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of *Helicobacter pylori* infection in adults. *GASTROENTEROLOGY*. 2016;151(1):51–69. doi:10.1053/j.gastro.2016.04.006
18. Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of *Helicobacter pylori* with triple 7–14 days and quadruple therapy in Turkey. *World J Gastroenterol*. 2004;10(5):668–671. doi:10.3748/wjg.v10.i5.668
19. Mascellino MT, Porowska B, De Angelis M, Oliva A. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in *Helicobacter pylori* infection. *Drug design devther*. 2017;11 (2209–2220).
20. Group CHPR, Gastroenterology CSO, Hong C, Fulian HU, Yong X, Pinjin HU. Prevalence of *Helicobacter pylori* resistance to antibiotics and its influence on the treatment outcome in China: a multicenter clinical study. *Chin J Gastroenter*. 2007;9:525–530.
21. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of *Helicobacter pylori* infection—the Maastricht v/florence consensus report. *GUT*. 2016;66(1):6–30.
22. Nishizawa T, Suzuki H. Mechanisms of *Helicobacter pylori* antibiotic resistance and molecular testing. *Fron Mol Biosci*. 2014;1. doi:10.3389/fmolb.2014.00019
23. Cattoir V, Nectoux J, Lascols C, et al. Update on fluoroquinolone resistance in *Helicobacter pylori*: new mutations leading to resistance and first description of a *gyrA* polymorphism associated with hypersusceptibility. *Int J Antimicrob Agents*. 2007;29(4):389–396. doi:10.1016/j.ijantimicag.2006.11.007
24. Miyachi H, Miki I, Aoyama N, et al. Primary levofloxacin resistance and *gyrA/B* mutations among *Helicobacter pylori* in Japan. *HELICOBACTER*. 2006;11(4):243–249. doi:10.1111/j.1523-5378.2006.00415.x
25. Singh V, Mishra S, Rao GRK, et al. Evaluation of nested PCR in detection of *Helicobacter pylori* targeting a highly conserved gene: HSP60. *HELICOBACTER*. 2008;13(1):30–34. doi:10.1111/j.1523-5378.2008.00573.x
26. CLSI. *Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria*. In: *Approved Standard—Third Edition. CLSI Document M45-A2*. vol. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
27. Shetty V, Lamichhane B, Tay CY, et al. High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in *Helicobacter pylori* isolated from Karnataka patients. *GUT PATHOG*. 2019;11(1):1. doi:10.1186/s13099-019-0305-x
28. HO S, EL TAN, CK SAM, GOH K. Clarithromycin resistance and point mutations in the 23S rRNA gene in *Helicobacter pylori* isolates from Malaysia. *J DIGEST DIS*. 2010;11(2):101–105. doi:10.1111/j.1751-2980.2010.00423.x
29. Wang L. Distribution of *gyrA* mutations in fluoroquinolone-resistant *Helicobacter pylori* strains. *WORLD J GASTROENTERO*. 2010;16 (18):2272. doi:10.3748/wjg.v16.i18.2272
30. Perez-Perez GI. Accurate diagnosis of *Helicobacter pylori*. Culture, including transport. *Gastroenterol Clin North Am*. 2000;29 (4):879–884. doi:10.1016/S0889-8553(05)70155-2
31. BJ HU, ZHAO FJ, ZL CHAI, et al. Prevalence and antibiotic resistance profile of *Helicobacter pylori* in Shanghai. *Chin J Infect Chemother*. 2016;16(3):346–352.
32. Wang YH, Li Z, Wang L, et al. A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in *Helicobacter pylori*. *Helicobacter*. 2018;23(2):e12467. doi:10.1111/hel.12467
33. Garcia M, Raymond J, Garnier M, Cremniter J, Burucoa C. Distribution of Spontaneous *gyrA* Mutations in 97 Fluoroquinolone-Resistant *Helicobacter pylori* Isolates Collected in France. *Antimicrobial Agents and Chemotherapy*. 2012;56 (1):550–551. doi:10.1128/AAC.05243-11
34. Boltin D, Ben-Zvi H, Perets TT, et al. Trends in secondary antibiotic resistance of *Helicobacter pylori* from 2007 to 2014: has the tide turned? *J Clin Microbiol*. 2015;53(2):522–527. doi:10.1128/JCM.03001-14
35. Horiki N, Omata F, Uemura M, et al. Annual change of primary resistance to clarithromycin among *Helicobacter pylori* isolates from 1996 through 2008 in Japan. *HELICOBACTER*. 2009;14(5):86–90. doi:10.1111/j.1523-5378.2009.00714.x
36. Kim JJ, Reddy R, Lee M, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of *Helicobacter pylori* isolates from Korea. *J Antimicrob Chemother*. 2001;47(4):459–461. doi:10.1093/jac/47.4.459
37. Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic resistance of *Helicobacter pylori* among male United States veterans. *Clin Gastroenterol Hepatol*. 2015;13(9):1616–1624. doi:10.1016/j.cgh.2015.02.005
38. Mitui M, Patel A, Leos NK, Doern CD, Park JY. Novel *Helicobacter pylori* sequencing test identifies high rate of clarithromycin resistance. *J Pediatr Gastroenterol Nutr*. 2014;59(1):6–9. doi:10.1097/MPG.0000000000000380
39. Saracino IM, Zullo A, Holton J, et al. High prevalence of primary antibiotic resistance in *Helicobacter pylori* isolates in Italy. *J Gastrointest Liver Dis*. 2012;21(4):363–365.
40. Cabrita J, Oleastro M, Matos R, et al. Features and trends in *Helicobacter pylori* antibiotic resistance in Lisbon area, Portugal (1990–1999). *J Antimicrob Chemother*. 2000;46(6):1029–1031. doi:10.1093/jac/46.6.1029
41. Li L, Ke Y, Yu C, et al. Antibiotic resistance of *Helicobacter pylori* in Chinese children: A multicenter retrospective study over 7 years. *HELICOBACTER*. 2017;22(3):e12373. doi:10.1111/hel.12373
42. Bouihat N, Burucoa C, Benkirane A, et al. *Helicobacter pylori* primary antibiotic resistance in 2015 in Morocco: a phenotypic and genotypic prospective and multicenter study. *Microb Drug Resist*. 2017;23(6):727–732. doi:10.1089/mdr.2016.0264
43. Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging *Helicobacter pylori* levofloxacin resistance and novel genetic mutation in Nepal. *BMC Microbiol*. 2016;16(1):1. doi:10.1186/s12866-016-0873-6

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>